(Q50641552)

17 March 2018

title

Impact of duration and dose of gonadotrophins on IVF outcomes. (English)

1 reference

17 March 2018

3

Aydin Arici

1 reference

17 March 2018

author name string

J Ryan Martin

series ordinal

1

1 reference

17 March 2018

Neal G Mahutte

series ordinal

2

1 reference

17 March 2018

Denny Sakkas

series ordinal

4

1 reference

17 March 2018

publication date

1 November 2006

1 reference

17 March 2018

Reproductive BioMedicine Online

published in

1 reference

17 March 2018

volume

13

1 reference

17 March 2018

issue

5

1 reference

17 March 2018

page(s)

645-650

1 reference

17 March 2018

A comparison of two starting doses of human menopausal gonadotrophin for follicle stimulation in unselected patients for in-vitro fertilization

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960654-2

7 January 2021

Follicular development and hormone concentrations following recombinant FSH administration for anovulation associated with polycystic ovarian syndrome: prospective, randomized comparison between low-dose step-up and modified step-down regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960654-2

7 January 2021

Recent trends in assisted reproductive techniques and associated outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960654-2

7 January 2021

FSH: what is the highest dose for ovarian stimulation that makes sense on an evidence-based level?

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960654-2

7 January 2021

Minimal ovarian stimulation for IVF: appraisal of potential benefits and drawbacks

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960654-2

7 January 2021

The need to step up the gonadotropin dosage in the stimulation phase of IVF treatment predicts a poor outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960654-2

7 January 2021

High-dose follicle-stimulating hormone stimulation at the onset of the menstrual cycle does not improve the in vitro fertilization outcome in low-responder patients

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960654-2

7 January 2021

Factors influencing response to ovarian stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960654-2

7 January 2021

Increasing the gonadotrophin dose in the course of an in vitro fertilization cycle does not rectify an initial poor response

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960654-2

7 January 2021

Recombinant gonadotrophins in reproductive medicine: gold standard for ovarian stimulation therapy in the 21st century

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960654-2

7 January 2021

The value of increasing the dose of human menopausal gonadotropins in women who initially demonstrate a poor response.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960654-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960654-2

1 reference

7 January 2021

Increasing the daily dose of recombinant follicle stimulating hormone (Puregon) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960654-2

7 January 2021

Outcome of assisted reproductive technology in women over the age of 41.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960654-2

7 January 2021

Factors influencing the cumulative conception rate and discontinuation of in vitro fertilization treatment for infertility.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960654-2

7 January 2021

Birth after the reimplantation of a human embryo

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960654-2

7 January 2021

Factors that affect outcome of in-vitro fertilisation treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960654-2

7 January 2021

10.1016/S1472-6483(10)60654-2

Identifiers

DOI

1 reference

17 March 2018

PubMed ID

17169173

1 reference

17 March 2018